1-methylthio-2-(2-methoxyethoxy)ethane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-methylthio-2-(2-methoxyethoxy)ethane
• 英文别名: 1-Methoxy-2-(2-methylsulfanylethoxy)ethane
• 化学式: C₆H₁₄O₂S
• 分子量: 150.242
• InChiKey: KAJFZTLENALYIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  43.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methylthio-2-(2-methoxyethoxy)ethane 、 碘甲烷 以 水 为溶剂， 反应 15.0h， 生成
  参考文献：
  名称：

  作为电化学应用的潜在电解质的醚官能化锍离子液体的合成和热物理性质。

  摘要：

  在这项工作中，合成并表征了一系列基于带有双{(三氟甲基)磺酰基}亚胺、[NTf 2 ] -阴离子的五种醚官能化锍阳离子的新型疏水性室温离子液体（IL）。测量了它们的物理化学性质，如密度、粘度和离子电导率、电化学窗口，以及热性质，包括相变行为和分解温度。所有这些离子液体都表现出大的液体温度范围、低粘度和良好的导电性。此外，通过将 DFT 计算与电化学表征相结合，这些新型离子液体显示出良好的电化学稳定性窗口，适合作为电化学储能装置中电解质材料的潜在应用。

  DOI：

  10.1002/cphc.201600882
• 作为产物：
  描述：

  1-溴-2-(2-甲氧基乙氧基)乙烷 、 sodium thiomethoxide 以 水 为溶剂， 反应 15.0h， 生成 1-methylthio-2-(2-methoxyethoxy)ethane
  参考文献：
  名称：

  作为电化学应用的潜在电解质的醚官能化锍离子液体的合成和热物理性质。

  摘要：

  在这项工作中，合成并表征了一系列基于带有双{(三氟甲基)磺酰基}亚胺、[NTf 2 ] -阴离子的五种醚官能化锍阳离子的新型疏水性室温离子液体（IL）。测量了它们的物理化学性质，如密度、粘度和离子电导率、电化学窗口，以及热性质，包括相变行为和分解温度。所有这些离子液体都表现出大的液体温度范围、低粘度和良好的导电性。此外，通过将 DFT 计算与电化学表征相结合，这些新型离子液体显示出良好的电化学稳定性窗口，适合作为电化学储能装置中电解质材料的潜在应用。

  DOI：

  10.1002/cphc.201600882

文献信息

• [EN] TREATMENT OF HELICOBACTER PYLORI INFECTIONS<br/>[FR] TRAITEMENT DES INFECTIONS À HELICOBACTER PYLORI
  申请人：EINSTEIN COLL MED

  公开号：WO2014025842A1

  公开（公告）日：2014-02-13

  Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5'-methylthioadenosine nucleosidase) to the subject.

  治疗幽门螺杆菌（H. pylori）感染的方法，特别是在患有消化性溃疡的患者中，包括向患者施用H. pylori MTAN（5'-甲硫腺苷核苷酸酶）抑制剂的方法。
• [EN] C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES<br/>[FR] OXAMYL DIPEPTIDES A TERMINAL C MODIFIE EN TANT QU'INHIBITEURS DE LA FAMILLE ICE/ced-3 DES PROTEASES DE CYSTEINE
  申请人：IDUN PHARMACEUTICALS INC

  公开号：WO2000001666A1

  公开（公告）日：2000-01-13

  This invention is directed to novel oxamyl depeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型的oxamyl depeptide ICE/ced-3家族抑制剂化合物。本发明还涉及含有这些化合物的制药组合物，以及在治疗患有炎症、自身免疫和神经退行性疾病的患者，预防缺血性损伤以及保护即将进行移植手术的器官中使用这些组合物的方法。
• Ketone compounds and compositions for cholesterol management and related uses
  申请人：Dasseux Henri Jean-Louis

  公开号：US20070155704A1

  公开（公告）日：2007-07-05

  The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新的酮类化合物、包含酮类化合物的组合物、以及用于治疗和预防心血管疾病、血脂异常、蛋白质异常和葡萄糖代谢紊乱的方法，包括给予含有酮类化合物的组合物。本发明的化合物、组合物和方法还可用于治疗和预防阿尔茨海默病、X综合征、过氧化物酶体增殖物激活受体相关疾病、败血症、血栓性疾病、肥胖症、胰腺炎、高血压、肾脏疾病、癌症、炎症和阳痿。在某些实施例中，本发明的化合物、组合物和方法可与其他治疗药物（如降胆固醇和降血糖药物）联合使用。
• C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
  申请人：Idun Pharmaceuticals, Inc.

  公开号：EP1091930A1

  公开（公告）日：2001-04-18
• Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications
  申请人：Glazier Arnold

  公开号：US20070172422A1

  公开（公告）日：2007-07-26

  The present invention relates to the compositions, methods, and applications of a new approach to pattern recognition based targeting by which an exponential amplification of effector response can be specifically obtained at a targeted cells. The purpose of this invention is to enable the selective delivery of large quantities of an array of effector molecules to target cells for diagnostic or therapeutic purposes. The invention is comprised of two components designated as “Compound 1” and “Compound 2”: Compound 1 is comprised of a cell binding agent and a masked female adaptor. Compound 2 is comprised of a male ligand, an effector agent, and two or more masked female receptors. The male ligand is selected to bind with high affinity to the female adaptor. Compound 1 can bind with high affinity to the target cell and the female receptor can then be unmasked by an enzyme enriched at the tumor cell. The male ligand of Compound 2 can then bind to the unmasked female adaptor bound to the target cell. The masked female adaptor on the bound Compound 2 can then be specifically unmasked. One receptor has in effect become two. Two new molecules of Compound 2 can bind to the unmasked adaptors receptors. After unmasking two receptors in effect become four. The process can continue in an explosive exponential like fashion resulting in enormous amplification of the number of effector molecules specifically deposited at the target cell.